BioAtla (NASDAQ:BCAB) Now Covered by Analysts at Rodman & Renshaw

Analysts at Rodman & Renshaw initiated coverage on shares of BioAtla (NASDAQ:BCAB) in a report issued on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $4.00 price target on the stock.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAtla in a research note on Friday. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BioAtla currently has a consensus rating of “Hold” and an average price target of $4.00.

BioAtla Stock Down 1.5%

Shares of NASDAQ BCAB traded down $0.00 during midday trading on Tuesday, reaching $0.31. The company had a trading volume of 4,305,481 shares, compared to its average volume of 2,499,553. The stock has a market cap of $18.22 million, a PE ratio of -0.27 and a beta of 1.04. BioAtla has a one year low of $0.24 and a one year high of $1.43. The firm’s fifty day moving average price is $0.74 and its 200-day moving average price is $0.61.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. As a group, equities research analysts expect that BioAtla will post -1.46 EPS for the current year.

Institutional Trading of BioAtla

Institutional investors have recently made changes to their positions in the company. Woodline Partners LP purchased a new stake in shares of BioAtla in the 1st quarter valued at approximately $26,000. Sheets Smith Investment Management purchased a new position in BioAtla during the 3rd quarter valued at about $46,000. Susquehanna International Group LLP grew its position in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares in the last quarter. Millennium Management LLC purchased a new stake in BioAtla during the third quarter worth about $235,000. Finally, Acadian Asset Management LLC increased its stake in BioAtla by 968.9% during the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares during the period. 77.23% of the stock is owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.